Information Provided By:
Fly News Breaks for June 11, 2019
Jun 11, 2019 | 05:58 EDT
Barclays analyst Balaji Prasad started Zoetis with an Overweight rating and $120 price target. The analyst launched coverage of 20 U.S. Specialty Pharmaceuticals with a Neutral industry view. He placed importance on cash flows and companies' ability to manage leverage and improve balance sheets.
News For ZTS From the Last 2 Days
Jul 22, 2019 | 07:56 EDT
Stifel analyst Jonathan Block said his checks indicate that a Triple combo product "is the most sought after future pharmaceutical product innovation that Veterinarians want to see" and he believes being first to market such a "Triple" can meaningfully increase Zoetis' market share in parasiticides. In addition to a Triple, Veterinarians' want for a product for feline pain, which Zoetis may introduce in 2021, noted Block, who raised his price target on Zoetis shares to $130 from $110 and keeps a Buy rating on the stock.